Biodistribution of etoposide via intratumoral chemotherapy with etoposide-loaded implants

References

• Al-Zu'bi MM, Mohan AS. (2019). Modelling of implantable drug delivery system in tumor microenvironment using molecular communication paradigm. IEEE Access 7:141929–40.
   Web of Science ®Google Scholar
• Ardizzoni A, Antonelli G, Grossi F, et al. (1999). The combination of etoposide and cisplatin in non-small-cell lung cancer (NSCLC). Ann Oncol 10 (Suppl 5):S13–S17.
   PubMed Web of Science ®Google Scholar
• Ashby LS, Smith KA, Stea B. (2016). Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature review. World J Surg Oncol 14:225.
   PubMed Web of Science ®Google Scholar
• Blanchemain N, Siepmann F, Siepmann J. (2017). [Implants for drug substance delivery]. Med Sci (Paris) 33:32–8.
   PubMed Web of Science ®Google Scholar
• Dong W, Zhang L, Niu Y, et al. (2013). A stable and practical etoposide-containing intravenous long-/medium-chain triglycerides-based lipid emulsion formulation: pharmacokinetics, biodistribution, toxicity, and antitumor efficacy. Expert Opin Drug Deliv 10:559–71.
   PubMed Web of Science ®Google Scholar
• Ezoe S. (2012). Secondary leukemia associated with the anti-cancer agent, etoposide, a topoisomerase II inhibitor. Int J Environ Res Public Health 9:2444–53.
   PubMed Web of Science ®Google Scholar
• Fitzgerald R, Bass LM, Goldberg DJ, et al. (2018). Physiochemical characteristics of poly-L-lactic acid (PLLA). Aesthet Surg J 38:S13–S17.
   PubMed Web of Science ®Google Scholar
• Gao L, Li Q, Zhang J, et al. (2019). Local penetration of doxorubicin via intrahepatic implantation of PLGA based doxorubicin-loaded implants. Drug Deliv 26:1049–57.
   PubMed Web of Science ®Google Scholar
• Gao L, Xie C, Du Y, et al. (2017). Characterization and antitumor efficacy of poly(L-lactid acid)-based etoposide-loaded implants. Drug Deliv 24:765–74.
   PubMed Web of Science ®Google Scholar
• Garrastazu Pereira G, Lawson AJ, Buttini F, Sonvico F. (2016). Loco-regional administration of nanomedicines for the treatment of lung cancer. Drug Deliv 23:2881–96.
   PubMed Web of Science ®Google Scholar
• Goldberg EP, Hadba AR, Almond BA, Marotta JS. (2002). Intratumoral cancer chemotherapy and immunotherapy: opportunities for nonsystemic preoperative drug delivery. J Pharm Pharmacol 54:159–80.
   PubMed Web of Science ®Google Scholar
• Hande KR. (1996). The importance of drug scheduling in cancer chemotherapy: etoposide as an example. Stem Cells 14:18–239.
   PubMed Web of Science ®Google Scholar
• Hande KR. (1998). Etoposide: four decades of development of a topoisomerase II inhibitor. Eur J Cancer 34:1514–21.
   PubMed Web of Science ®Google Scholar
• Heldin CH, Rubin K, Pietras K, Ostman A. (2004). High interstitial fluid pressure – an obstacle in cancer therapy. Nat Rev Cancer 4:806–13.
   PubMed Web of Science ®Google Scholar
• Hohenforst-Schmidt W, Zarogoulidis P, Darwiche K, et al. (2013). Intratumoral chemotherapy for lung cancer: re-challenge current targeted therapies. Drug Des Devel Ther 7:571–83.
   PubMed Web of Science ®Google Scholar
• Krukiewicz K, Zak JK. (2016). Biomaterial-based regional chemotherapy: local anticancer drug delivery to enhance chemotherapy and minimize its side-effects. Mater Sci Eng C Mater Biol Appl 62:927–42.
   PubMed Web of Science ®Google Scholar
• Kumabe T, Shibahara I, Saito R, et al. (2018). Results for Treatment of Newly-Diagnosed Glioblastoma Using Carmustine Wafers(Gliadel®). No Shinkei Geka 46:367–76.
   PubMedGoogle Scholar
• Kumar P, Wasim L, Chopra M, Chhikara A. (2018). Co-delivery of vorinostat and etoposide via disulfide cross-linked biodegradable polymeric nanogels: synthesis, characterization, biodegradation, and anticancer activity. AAPS PharmSciTech 19:634–47.
   PubMed Web of Science ®Google Scholar
• Li C, Cheng L, Zhang Y, et al. (2010). Effects of implant diameter, drug loading and end-capping on praziquantel release from PCL implants. Int J Pharm 386:23–9.
   PubMed Web of Science ®Google Scholar
• Li F, Wang Y, Chen WL, et al. (2019). Co-delivery of VEGF siRNA and etoposide for enhanced anti-angiogenesis and anti-proliferation effect via multi-functional nanoparticles for orthotopic non-small cell lung cancer treatment. Theranostics 9:5886–98.
   PubMed Web of Science ®Google Scholar
• LiverTox. LiverTox: clinical and research information on drug-induced liver injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–2018. Available at: https://www.ncbi.nlm.nih.gov/books/NBK548102/
   Google Scholar
• Lu B, Sun L, Yan X, et al. (2015). Intratumoral chemotherapy with paclitaxel liposome combined with systemic chemotherapy: a new method of neoadjuvant chemotherapy for stage III unresectable non-small cell lung cancer. Med Oncol 32:345.
   PubMed Web of Science ®Google Scholar
• Montecucco A, Zanetta F, Biamonti G. (2015). Molecular mechanisms of etoposide. Excli J 14:95–108.
   PubMed Web of Science ®Google Scholar
• Najar IA, Johri RK. (2014). Pharmaceutical and pharmacological approaches for bioavailability enhancement of etoposide. J Biosci 39:139–44.
   PubMed Web of Science ®Google Scholar
• Nanaki SG, Spyrou K, Bekiari C, et al. (2020). Hierarchical porous carbon-PLLA and PLGA hybrid nanoparticles for intranasal delivery of galantamine for alzheimer's disease therapy. Pharmaceutics 12:227.
   PubMed Web of Science ®Google Scholar
• Popova P, Notabi MK, Code C, et al. (2019). Co-delivery of siRNA and etoposide to cancer cells using an MDEA esterquat based drug delivery system. Eur J Pharm Sci 127:142–50.
   PubMed Web of Science ®Google Scholar
• Ramesh B, Cherian KM, Fakoya AOJ, et al. (2020). Fabrication and electrospinning of 3D biodegradable poly-l-lactic acid (PLLA) nanofibers for clinical application. Methods Mol Biol 2125:119–28.
   PubMedGoogle Scholar
• Saltzman WM, Fung LK. (1997). Polymeric implants for cancer chemotherapy. Adv Drug Deliv Rev 26:209–30.
   PubMed Web of Science ®Google Scholar
• Solano AG, de Fatima Pereira A, Pinto FC, et al. (2013). Development and evaluation of sustained-release etoposide-loaded poly(ε-caprolactone) implants. AAPS PharmSciTech 14:890–900.
   PubMed Web of Science ®Google Scholar
• The Pharmacopoeia Commission of the People’s Republic of China. The Pharmacopoeia of the People’s Republic of China. Beijing: China Medical Science Press; 2019.
   Google Scholar
• U.S. Department of Health and Human Services, Food and Drug Administration (FDA), Center for Drug Evaluation and Research. 2018. Guidance for industry, bioanalytical method validation. Available at: https://www.fda.gov/media/70858/download
   Google Scholar
• Weinberg BD, Blanco E, Gao J. (2008). Polymer implants for intratumoral drug delivery and cancer therapy. J Pharm Sci 97:1681–702.
   PubMed Web of Science ®Google Scholar
• Yuan ZQ, Chen WL, You BG, et al. (2017). Multifunctional nanoparticles co-delivering EZH2 siRNA and etoposide for synergistic therapy of orthotopic non-small-cell lung tumor. J Control Release 268:198–211.
   PubMed Web of Science ®Google Scholar
• Zhang M, Tang Y, Zhu Z, et al. (2018). Paclitaxel and etoposide-loaded poly (lactic-co-glycolic acid) microspheres fabricated by coaxial electrospraying for dual drug delivery. J Biomater Sci Polym Ed 29:1949–63.
   PubMed Web of Science ®Google Scholar